PHK
CADL icon

Point72 Hong Kong’s Candel Therapeutics CADL Stock Holding History

Point72 Hong Kong’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-640
Closed -$2K – 1963
2022
Q2 		$2K Buy
+640
New +$2.56K ﹤0.01% 1782

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's CADL Position: Q3 2022 in Review

Point72 Hong Kong sold out of Candel Therapeutics (CADL) in Q3 2022, closing a stake of 640 shares — an estimated $2K sold.

Point72 Hong Kong first reported a position in CADL in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 25 funds tracked by Wall St. Rank hold CADL as of Q3 2022.

  • Point72 Hong Kong reported no remaining Candel Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 640 Candel Therapeutics shares in Q3 2022, an estimated $2K.
  • Point72 Hong Kong first reported a position in Candel Therapeutics in Q2 2022 and held it in 1 quarter.
  • Point72 Hong Kong's Candel Therapeutics position peaked at $2K in Q2 2022.
  • 25 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.